DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

• Published in: Signal transduction and targeted therapy Vol. 5; no. 1; p. 60
• Main Authors: Huang, Rui-Xue, Zhou, Ping-Kun
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-05-2020; Nature Publishing Group
• Subjects: 631/80; 692/308/2056; Cancer Research; Cell Biology; Cell cycle; Cell Cycle Checkpoints - radiation effects; Deoxyribonucleic acid; DNA; DNA Breaks, Double-Stranded - radiation effects; DNA damage; DNA Repair - radiation effects; Humans; Internal Medicine; Kinases; Medicine; Medicine & Public Health; Neoplasm Proteins - metabolism; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - radiotherapy; Oncology; Pathology; Radiation therapy; Radiation Tolerance; Radiotherapy; Review; Review Article; Signal transduction; Signal Transduction - radiation effects
• ISSN: 2059-3635; 2095-9907; 2059-3635
• DOI: 10.1038/s41392-020-0150-x

Radiotherapy is one of the most common countermeasures for treating a wide range of tumors. However, the radioresistance of cancer cells is still a major limitation for radiotherapy applications. Efforts are continuously ongoing to explore sensitizing targets and develop radiosensitizers for improving the outcomes of radiotherapy. DNA double-strand breaks are the most lethal lesions induced by ionizing radiation and can trigger a series of cellular DNA damage responses (DDRs), including those helping cells recover from radiation injuries, such as the activation of DNA damage sensing and early transduction pathways, cell cycle arrest, and DNA repair. Obviously, these protective DDRs confer tumor radioresistance. Targeting DDR signaling pathways has become an attractive strategy for overcoming tumor radioresistance, and some important advances and breakthroughs have already been achieved in recent years. On the basis of comprehensively reviewing the DDR signal pathways, we provide an update on the novel and promising druggable targets emerging from DDR pathways that can be exploited for radiosensitization. We further discuss recent advances identified from preclinical studies, current clinical trials, and clinical application of chemical inhibitors targeting key DDR proteins, including DNA-PKcs (DNA-dependent protein kinase, catalytic subunit), ATM/ATR (ataxia–telangiectasia mutated and Rad3-related), the MRN (MRE11-RAD50-NBS1) complex, the PARP (poly[ADP-ribose] polymerase) family, MDC1, Wee1, LIG4 (ligase IV), CDK1, BRCA1 (BRCA1 C terminal), CHK1, and HIF-1 (hypoxia-inducible factor-1). Challenges for ionizing radiation-induced signal transduction and targeted therapy are also discussed based on recent achievements in the biological field of radiotherapy.